A carregar...
Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
BACKGROUND: There are no head-to-head randomised controlled trials (RCTs) comparing the effectiveness of biologics in ulcerative colitis (UC). We aimed to assess the cost-effectiveness of adalimumab, infliximab and vedolizumab as first-line agents to induce clinical remission and mucosal healing (MH...
Na minha lista:
| Publicado no: | BMJ Open Gastroenterol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4860720/ https://ncbi.nlm.nih.gov/pubmed/27195130 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjgast-2016-000093 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|